Trial Outcomes & Findings for Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion Syndrome (NCT NCT05647304)
NCT ID: NCT05647304
Last Updated: 2025-03-10
Results Overview
Percentage of patients with at least one ADE
COMPLETED
NA
50 participants
Throughout the investigation (from Day 0 to Day 52)
2025-03-10
Participant Flow
Recruitment period : 11 October 2022 - 02 May 2023 One site located in France
Participant milestones
| Measure |
5 Hz-PWM
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Overall Study
STARTED
|
26
|
24
|
|
Overall Study
COMPLETED
|
25
|
24
|
|
Overall Study
NOT COMPLETED
|
1
|
0
|
Reasons for withdrawal
| Measure |
5 Hz-PWM
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
0
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
Total
n=50 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
24.9 years
STANDARD_DEVIATION 5.2 • n=26 Participants
|
25.1 years
STANDARD_DEVIATION 5.1 • n=24 Participants
|
25.0 years
STANDARD_DEVIATION 5.1 • n=50 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=26 Participants
|
3 Participants
n=24 Participants
|
6 Participants
n=50 Participants
|
|
Sex: Female, Male
Male
|
23 Participants
n=26 Participants
|
21 Participants
n=24 Participants
|
44 Participants
n=50 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
France
|
26 participants
n=26 Participants
|
24 participants
n=24 Participants
|
50 participants
n=50 Participants
|
|
Time between concussion and inclusion
|
2.4 days
STANDARD_DEVIATION 0.5 • n=26 Participants
|
2.3 days
STANDARD_DEVIATION 0.4 • n=24 Participants
|
2.3 days
STANDARD_DEVIATION 0.5 • n=50 Participants
|
|
Concussion history
|
2.0 concussion
STANDARD_DEVIATION 2.1 • n=26 Participants
|
1.4 concussion
STANDARD_DEVIATION 1.6 • n=24 Participants
|
1.7 concussion
STANDARD_DEVIATION 1.9 • n=50 Participants
|
PRIMARY outcome
Timeframe: Throughout the investigation (from Day 0 to Day 52)Population: Patients randomized and treated at least once (at inclusion visit)
Percentage of patients with at least one ADE
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Incidence of RGn550's Adverse Device Effects (ADEs)
|
10 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: Throughout the investigation (from Day 0 to Day 52)Population: Patients randomized and treated at least once (at inclusion visit)
Percentage of patients with at least one ADE per severity (mild, moderate and severe)
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one mild ADE
|
10 Participants
|
10 Participants
|
|
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one moderate ADE
|
0 Participants
|
0 Participants
|
|
Incidence of RGn550's ADEs Per Severity (Mild, Moderate and Severe)
Patients who had at least one severe ADE
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Throughout the investigation (from Day 0 to Day 52)Population: Patients randomized and treated at least once (at inclusion visit)
Percentage of patients with at least one AE
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Incidence of RGn550's Adverse Events (AEs)
|
12 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: Throughout the investigation (from Day 0 to Day 52)Population: Patients randomized and treated at least once (at inclusion visit)
Percentage of patients with at least one DD
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Incidence of RGn550's Device Deficiencies (DDs)
|
4 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the Near Point of Convergence (NPC)
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D0 before treatment
|
4.6 NPC (cm)
Standard Deviation 5.6
|
2.9 NPC (cm)
Standard Deviation 3.1
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D0 after treatment
|
1.8 NPC (cm)
Standard Deviation 2.6
|
0.4 NPC (cm)
Standard Deviation 1.2
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D7 before treatment
|
1.3 NPC (cm)
Standard Deviation 2.1
|
0.3 NPC (cm)
Standard Deviation 0.8
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D7 after treatment
|
1.0 NPC (cm)
Standard Deviation 1.8
|
0.1 NPC (cm)
Standard Deviation 0.4
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through the Convergence
D52
|
0.9 NPC (cm)
Standard Deviation 1.8
|
0.4 NPC (cm)
Standard Deviation 1.0
|
SECONDARY outcome
Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the deviation assessed via the Cover test considering both eyes The unilateral cover test was used in this investigation, which consists into covering one eye, horizontally moving a target 5 cm in front of both eyes, and then uncovering the covered eye and observing its reaction. If it fixes the target, this is normal: there is an orthophoria. If it moves to fix the target (restitution movement), the test is positive: there is a heterophoria in near vision. Patients who had visual corrections were to keep them during the test. The test was then repeated on the other eye. The outcome of this test was a deviation value, considering both eyes, comprised between 0 (better outcome = normal fixation) and 3 (worst outcome = deviated eye without restitution movement).
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D0 before treatment
|
1.5 score on a scale
Standard Deviation 0.9
|
1.5 score on a scale
Standard Deviation 1.0
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D0 after treatment
|
0.9 score on a scale
Standard Deviation 1.0
|
1.0 score on a scale
Standard Deviation 1.0
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D7 before treatment
|
1.0 score on a scale
Standard Deviation 0.9
|
0.8 score on a scale
Standard Deviation 1.0
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D52
|
0.8 score on a scale
Standard Deviation 1.1
|
0.5 score on a scale
Standard Deviation 0.8
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
D7 after treatment
|
0.6 score on a scale
Standard Deviation 1.0
|
0.6 score on a scale
Standard Deviation 0.8
|
SECONDARY outcome
Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the deviations assessed via Maddox rod test (horizontal deviation, vertical deviation of at least one eye)
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D7 before treatment
|
12 Participants
|
11 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D7 after treatment
|
10 Participants
|
10 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D0 before treatment
|
18 Participants
|
17 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D0 after treatment
|
11 Participants
|
13 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Horizontal deviation : D52
|
11 Participants
|
14 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D0 before treatment
|
9 Participants
|
7 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D0 after treatment
|
4 Participants
|
4 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D7 before treatment
|
4 Participants
|
1 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D7 after treatment
|
2 Participants
|
1 Participants
|
|
Evolution of Automated Oculomotor and Oculopostural Functions, as Assessed Through Deviations
Vertical deviation of at least one eye : D52
|
3 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of statokinesigram area with closed eyes The statokinesigram is the projection onto a 2-dimensional space of the trajectory of the patient's center of pressure. Its area is measured in mm2. The larger the area is, the higher the patient's imbalance is. The statokinesigram area was measured using the stabilometric platform KFORCE Plates on which the patients were asked to stand for 30 s with closed eyes.
Outcome measures
| Measure |
5 Hz-PWM
n=25 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 before treatment
|
51.9 mm2
Standard Deviation 28.9
|
54.9 mm2
Standard Deviation 41.4
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D52
|
50.9 mm2
Standard Deviation 33.9
|
51.9 mm2
Standard Deviation 39.5
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 after treatment
|
64.4 mm2
Standard Deviation 50.5
|
62.9 mm2
Standard Deviation 60.2
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 before treatment
|
51.0 mm2
Standard Deviation 34.3
|
56.8 mm2
Standard Deviation 33.2
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 after treatment
|
47.9 mm2
Standard Deviation 31.2
|
59.9 mm2
Standard Deviation 41.9
|
SECONDARY outcome
Timeframe: at Day 0 and Day 7 (before and after treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the difference between left and right distributions of patient's body weight Patient's body weight left distribution, respectively right distribution, refer to patient's body weight distribution on his/her left foot, respectively right foot. The left distribution and the right distribution are two percentages which sum makes 100%. When body weight is well distributed between left and right feet (coherent balance), the difference between left and right distributions is ≤ 5%. When body weight is not well distributed between left and right feet (uncoherent balance), the difference between left and right distributions is \> 5%. These distributions were measured using the stabilometric platform KFORCE Plates on which the patients were asked to stand for 30 s with closed eyes.
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 after treatment
|
6.9 % of body weight distribution difference
Standard Deviation 4.3
|
6.3 % of body weight distribution difference
Standard Deviation 5.0
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D0 before treatment
|
6.5 % of body weight distribution difference
Standard Deviation 4.1
|
6.3 % of body weight distribution difference
Standard Deviation 4.7
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 before treatment
|
5.7 % of body weight distribution difference
Standard Deviation 3.5
|
7.5 % of body weight distribution difference
Standard Deviation 5.7
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D7 after treatment
|
5.0 % of body weight distribution difference
Standard Deviation 4.7
|
5.2 % of body weight distribution difference
Standard Deviation 4.1
|
|
Evolution of the Balance Function, as Assessed Through Static Stabilometric Parameters
D52
|
6.0 % of body weight distribution difference
Standard Deviation 5.1
|
6.4 % of body weight distribution difference
Standard Deviation 4.5
|
SECONDARY outcome
Timeframe: at Day 0 (before treatment session) and at Day 7 (after treatment session) Of note: for 46 patients, TMTB was performed before (rather than after) treatment at D7 (deviation)Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the Trail Making Test part A and B (TMT A\&B) time to perform the task
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTA time to perform the task: D0
|
19.0 s
Standard Deviation 5.4
|
21.2 s
Standard Deviation 7.0
|
|
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTA time to perform the task: D7
|
15.7 s
Standard Deviation 4.0
|
18.5 s
Standard Deviation 4.8
|
|
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTB time to perform the task: D0
|
53.5 s
Standard Deviation 20.1
|
50.9 s
Standard Deviation 26.6
|
|
Evolution of Executive Function, as Assessed With the Trail Making Test Part A and B (TMT A&B)
TMTB time to perform the task: D7
|
42.5 s
Standard Deviation 12.7
|
43.1 s
Standard Deviation 17.9
|
SECONDARY outcome
Timeframe: at baseline (which represents the patient's state before the concussion as estimated/assessed by the patient on D0), Day 0 (before treatment session), Day 7 (before treatment session), Day 14 and Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the SCAT5 (Sport Concussion Assessment Tool - 5th edition) score The SCAT5 is a standardized tool for evaluating concussions designed for use by physicians and licensed healthcare professionals. With this tool, the patient rates the intensity of every symptom from 0 (none) to 6 (severe) using a form. This enables to calculate the total number of symptoms (subscore from 0 to 22) and the symptom severity score (subscore from 0 to 132).
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D7 before treatment
|
1.2 score on a scale
Standard Deviation 2.2
|
1.7 score on a scale
Standard Deviation 4.2
|
|
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D0 before treatment
|
7.5 score on a scale
Standard Deviation 7.4
|
10.8 score on a scale
Standard Deviation 13.2
|
|
Evolution of Concussion Syndrome Symptoms
Total number of symptoms: baseline
|
0.4 score on a scale
Standard Deviation 0.8
|
0.3 score on a scale
Standard Deviation 0.4
|
|
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D0 before treatment
|
4.6 score on a scale
Standard Deviation 3.7
|
5.5 score on a scale
Standard Deviation 4.7
|
|
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D14
|
0.4 score on a scale
Standard Deviation 1.1
|
1.3 score on a scale
Standard Deviation 4.0
|
|
Evolution of Concussion Syndrome Symptoms
Total number of symptoms : D52
|
0.2 score on a scale
Standard Deviation 0.6
|
0.8 score on a scale
Standard Deviation 3.1
|
|
Evolution of Concussion Syndrome Symptoms
Symptom severity score: baseline
|
0.7 score on a scale
Standard Deviation 1.5
|
0.4 score on a scale
Standard Deviation 0.8
|
|
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D7 before treatment
|
2.1 score on a scale
Standard Deviation 4.2
|
3.5 score on a scale
Standard Deviation 11.9
|
|
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D14
|
0.8 score on a scale
Standard Deviation 2.2
|
2.9 score on a scale
Standard Deviation 11.1
|
|
Evolution of Concussion Syndrome Symptoms
Symptom severity score: D52
|
0.3 score on a scale
Standard Deviation 1.2
|
2.1 score on a scale
Standard Deviation 9.2
|
SECONDARY outcome
Timeframe: at Day 0 (before treatment session) and at Day 52Population: Patients randomized and treated at least once (at inclusion visit)
Evolution of the concentration of: * Anti-inflammatory cytokines InterLeukin (IL)-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11 and IL-13 * S100 calcium binding protein B (S100B) * Glial Fibrillary Acidic Protein (GFAP) * Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) Of note: IL-11 and IL-13 could eventually not be analyzed due to undetectable low concentrations
Outcome measures
| Measure |
5 Hz-PWM
n=26 Participants
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 Participants
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Evolution of the Concussion Blood Markers
GFAP : D52
|
67.7 pg/mL
Standard Deviation 29.6
|
49.8 pg/mL
Standard Deviation 21.5
|
|
Evolution of the Concussion Blood Markers
UCHL1 : D0 before treatment
|
11.0 pg/mL
Standard Deviation 20.4
|
3.9 pg/mL
Standard Deviation 4.4
|
|
Evolution of the Concussion Blood Markers
UCHL1 : D52
|
9.3 pg/mL
Standard Deviation 13.3
|
5.0 pg/mL
Standard Deviation 4.5
|
|
Evolution of the Concussion Blood Markers
IL-1RA : D0 before treatment
|
367.8 pg/mL
Standard Deviation 231.8
|
413.3 pg/mL
Standard Deviation 318.7
|
|
Evolution of the Concussion Blood Markers
IL-1RA : D52
|
324.2 pg/mL
Standard Deviation 122.5
|
452.5 pg/mL
Standard Deviation 423.8
|
|
Evolution of the Concussion Blood Markers
IL-10 : D0 before treatment
|
0.74 pg/mL
Standard Deviation 1.88
|
0.33 pg/mL
Standard Deviation 0.16
|
|
Evolution of the Concussion Blood Markers
IL-4 : D52
|
0.05 pg/mL
Standard Deviation 0.05
|
0.05 pg/mL
Standard Deviation 0.04
|
|
Evolution of the Concussion Blood Markers
IL-6 : D0 before treatment
|
1.25 pg/mL
Standard Deviation 2.32
|
2.36 pg/mL
Standard Deviation 3.44
|
|
Evolution of the Concussion Blood Markers
IL-6 : D52
|
0.97 pg/mL
Standard Deviation 1.85
|
1.35 pg/mL
Standard Deviation 2.19
|
|
Evolution of the Concussion Blood Markers
S100B : D0 before treatment
|
25.7 pg/mL
Standard Deviation 35.4
|
17.6 pg/mL
Standard Deviation 10.9
|
|
Evolution of the Concussion Blood Markers
GFAP : D0 before treatment
|
95.3 pg/mL
Standard Deviation 75.6
|
82.5 pg/mL
Standard Deviation 40.2
|
|
Evolution of the Concussion Blood Markers
IL-10 : D52
|
0.28 pg/mL
Standard Deviation 0.08
|
0.51 pg/mL
Standard Deviation 0.47
|
|
Evolution of the Concussion Blood Markers
IL-4 : D0 before treatment
|
0.02 pg/mL
Standard Deviation 0.01
|
0.02 pg/mL
Standard Deviation 0.01
|
|
Evolution of the Concussion Blood Markers
S100B : D52
|
25.0 pg/mL
Standard Deviation 36.0
|
17.2 pg/mL
Standard Deviation 10.5
|
Adverse Events
5 Hz-PWM
10 Hz-PWM
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
5 Hz-PWM
n=26 participants at risk
RGn550 with a 5 Hz-pulsed wave mode light emission
RGn550 5 Hz-PWM: RGn550 with a 5 Hz-pulsed wave mode light emission
|
10 Hz-PWM
n=24 participants at risk
RGn550 with a 10 Hz-pulsed wave mode light emission
RGn550 10 Hz-PWM: RGn550 with a 10 Hz-pulsed wave mode light emission
|
|---|---|---|
|
Eye disorders
Photophobia
|
0.00%
0/26 • Throughout the investigation (from D0 to D52)
|
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
|
General disorders
Fatigue
|
0.00%
0/26 • Throughout the investigation (from D0 to D52)
|
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
|
General disorders
Medical device site discomfort
|
19.2%
5/26 • Number of events 5 • Throughout the investigation (from D0 to D52)
|
16.7%
4/24 • Number of events 4 • Throughout the investigation (from D0 to D52)
|
|
General disorders
Medical device site warmth
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/26 • Throughout the investigation (from D0 to D52)
|
4.2%
1/24 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
|
Injury, poisoning and procedural complications
Concussion
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
0.00%
0/24 • Throughout the investigation (from D0 to D52)
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
0.00%
0/24 • Throughout the investigation (from D0 to D52)
|
|
Nervous system disorders
Headache
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
0.00%
0/24 • Throughout the investigation (from D0 to D52)
|
|
Nervous system disorders
Hypersomnia
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
0.00%
0/24 • Throughout the investigation (from D0 to D52)
|
|
Nervous system disorders
Somnolence
|
23.1%
6/26 • Number of events 6 • Throughout the investigation (from D0 to D52)
|
33.3%
8/24 • Number of events 9 • Throughout the investigation (from D0 to D52)
|
|
Psychiatric disorders
Irritability
|
3.8%
1/26 • Number of events 1 • Throughout the investigation (from D0 to D52)
|
0.00%
0/24 • Throughout the investigation (from D0 to D52)
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee If the investigators wish to publish data from this investigation (poster, abstract, article, etc.), they must first seek approval from REGEnLIFE.
- Publication restrictions are in place
Restriction type: OTHER